Drugs / SGX523
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00606879 | Jan 2008 → Jan 2009 | — | SGX Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT00607399 | Jan 2008 → Jan 2009 | — | SGX Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGX523 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00607399 ↗ |
| Action | Inhibit | “acts by blocking the function of an enzyme called MET” NCT00606879 ↗ |
| Modality | Small molecule | “a Small Molecule Met Inhibitor” NCT00606879 ↗ |
| Route | Oral | “Orally Administered” NCT00606879 ↗ |
| Target | MET | “blocking the function of an enzyme called MET” NCT00607399 ↗ |